Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine.
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Rimegepant (Primary) ; Sumatriptan
- Indications Migraine
- Focus Therapeutic Use
- 27 Nov 2017 Primary endpoint (Pain Freedom (from migraine pain)) has been met according to a Biohaven Pharmaceutical Holding Company.
- 12 Aug 2013 Results published in Cephalalgia.
- 30 Jun 2013 Results presented at the 2013 International Headache Congress .
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History